Drug General Information (ID: DDIGHZ9USF)
Drug Name			Fingolimod		Drug Info		Measles virus vaccine live attenuated		Drug Info
Drug Type		Small molecule				Vaccine
Therapeutic Class		Selective Immunosuppressants				Vaccine

Mechanism of Fingolimod-Measles virus vaccine live attenuated Interaction (Severity Level: Major)
Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Drug Name		Fingolimod				Measles virus vaccine live attenuated
Mechanism		Immunosuppressive effects				Vaccine or toxoid
Key Mechanism Factor 1
		Factor Name		Vaccine/toxoid
		Factor Description		The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
Mechanism Description		Antagonize the effect of Measles virus vaccine live attenuated when combined with Fingolimod

Recommended Action
Management		The use of live attenuated vaccines should be avoided during and for two months after treatment with fingolimod. In patients who have recently been vaccinated, fingolimod therapy should be postponed for one month to allow the full effect of vaccination to occur.

References
1	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
2	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
3	Product Information. Meruvax II (rubella virus vaccine, live). Merck &amp Co, Inc, West Point, PA.